By admin 
In a landmark decision that signifies a paradigm shift in respiratory virus prevention, the Food and Drug Administration on Wednesday granted approval to Moderna’s influenza vaccine for older adults, marking the first time a messenger RNA (mRNA) flu shot has been licensed for use in the United States. The vaccine, which will be marketed under the brand name mFlusiva, represents Moderna’s fourth commercial product to enter the American market, solidifying the company’s transition from a pandemic-focused entity to a diversified powerhouse in the respiratory vaccine sector.
The approval follows a tumultuous regulatory journey that, just six months ago, appeared to be at a total standstill. In February, the path for mFlusiva was nearly derailed when Vinay Prasad, then the FDA’s head of biologics, took the extraordinary step of overturning the recommendations of his career staff. Prasad issued a rare “refusal-to-file” notice to Moderna, a move that effectively signaled the agency’s intent to not even begin a formal review of the vaccine based on the submitted data package. The primary point of contention involved the clinical trial design, specifically whether Moderna had compared its mRNA candidate against the appropriate benchmarks for the elderly population.
However, the regulatory standoff was short-lived. Within a week of the refusal—and following a public disclosure by Moderna that highlighted the company’s significant displeasure with the agency’s stance—Prasad’s decision was reversed. This internal FDA reversal allowed the review process to proceed, eventually leading to a positive recommendation from the agency’s independent advisors. The saga concluded with Prasad’s departure from the FDA at the end of April, leaving a vacancy at the helm of the Center for Biologics Evaluation and Research (CBER) during a critical period of vaccine innovation.
Moderna CEO Stéphane Bancel hailed the approval as a triumph for both public health and the mRNA platform. “Flu remains a significant public health challenge, and mFLUSIVA provides an important new option for America’s seniors,” Bancel said in a statement. “This approval also reflects the ongoing potential of our mRNA platform to help address important public health challenges through continued scientific innovation.” The company has indicated that it is moving rapidly to integrate the vaccine into the national supply chain, with expectations that doses will be available for administration in advance of the upcoming fall flu season.
The FDA’s regulatory action on Wednesday was bifurcated by age group, reflecting the nuances of the clinical data presented. The agency issued a standard approval for adults aged 50 to 64, a demographic where the vaccine showed robust efficacy against circulating strains. For adults aged 65 and older, the FDA granted an accelerated approval. This pathway allows for the earlier licensing of products that treat serious conditions and fill an unmet medical need based on a surrogate endpoint. As a condition of this accelerated approval, Moderna has committed to conducting a Phase 4 post-licensure trial. This study will be designed to gather more granular effectiveness data, specifically comparing mFlusiva’s performance against existing high-dose or adjuvanted vaccines—such as Sanofi’s Fluzone High-Dose or CSL Seqirus’s Fluad—which are currently the preferentially recommended options for seniors due to their enhanced immune response.
The entry of an mRNA vaccine into the crowded influenza market introduces a new technological front in the fight against a virus that causes between 12,000 and 52,000 deaths annually in the U.S. alone. For decades, the flu vaccine market has been dominated by traditional manufacturing methods. Most existing vaccines are produced using chicken eggs, a process that has remained largely unchanged for over 70 years. While cell-based production has offered some improvements in recent years, both methods suffer from a significant drawback: a long lead time.
Every year, the World Health Organization (WHO) and national health agencies must select the viral strains for the upcoming season’s vaccine months in advance to allow for the lengthy manufacturing process. This "best guess" approach often leads to a "mismatch" if the circulating virus mutates in the intervening months, significantly reducing vaccine effectiveness. Furthermore, the process of growing human influenza viruses in eggs can lead to "egg-adapted" mutations, which may make the vaccine less effective against the actual viruses circulating in the community.
The mRNA technology utilized in mFlusiva bypasses these biological hurdles. Because mRNA vaccines are chemically synthesized rather than grown in biological cultures, they can be designed and manufactured much more rapidly. Theoretically, this speed allows health officials to wait longer to finalize the strain selection, potentially resulting in a vaccine that more closely matches the viruses actually circulating during the winter months. Beyond seasonal benefits, this manufacturing agility is viewed by biosecurity experts as a critical asset for pandemic preparedness. Should a highly pathogenic strain of avian influenza (such as H5N1) begin to spread efficiently among humans, the existence of a licensed mRNA seasonal flu infrastructure would provide a "warm" manufacturing base, drastically shortening the timeline to produce a pandemic-specific shot.
The clinical profile of mFlusiva was a central focus of the Vaccines and Related Biological Products Advisory Committee (VRBPAC) meeting in June. The committee, composed of independent scientific experts, voted unanimously that the benefits of the vaccine outweighed its risks. Data presented during the meeting showed that in the 50-to-64 age group, participants who received mFlusiva were 27% less likely to contract test-confirmed influenza compared to those who received a standard-dose traditional vaccine. This margin of improvement is significant in the context of influenza, where even small increases in efficacy can prevent thousands of hospitalizations across a national population.
However, the mRNA platform’s potency comes with a trade-off in reactogenicity. Trial data indicated that while the safety profile was generally favorable, there were substantially more side effects reported in the mRNA arm than in the traditional vaccine arm. These side effects, which included injection site pain, fatigue, and headache, were characterized as mostly mild to moderate and typically resolved within 24 to 48 hours. For many public health officials, this "higher reactogenicity" is a known characteristic of the mRNA platform—previously seen with COVID-19 vaccines—and is often viewed as a sign of a robust immune system response.
The controversy involving Vinay Prasad earlier this year centered on the "comparator" problem. In the U.S., the Advisory Committee on Immunization Practices (ACIP) recommends that adults 65 and older receive "enhanced" flu vaccines—either high-dose, adjuvanted, or recombinant—because standard-dose vaccines are often less effective in the aging immune system. Prasad’s initial objection was based on Moderna’s decision to use a standard-dose vaccine as the comparator in its Phase 3 trial for the 65+ group, rather than one of these enhanced options.
In a letter defending his initial refusal-to-file, Prasad noted that the FDA had communicated these expectations to Moderna before the trials commenced. Moderna, however, countered by releasing documents suggesting the agency’s guidance was not a definitive requirement. The company further argued that its Phase 3 trial was conducted across 11 countries, many of which do not routinely use or recommend high-dose or adjuvanted vaccines for their senior populations. By using a standard-dose comparator, Moderna argued it was adhering to a global baseline of care. The eventual reversal by the FDA and the subsequent accelerated approval for the 65+ group suggests a compromise: the vaccine can enter the market now, but Moderna must prove its worth against the "gold standard" high-dose shots in the coming years.
The approval of mFlusiva is likely to trigger a new wave of competition in the multibillion-dollar influenza vaccine market. Established players like Sanofi, GSK, and CSL Seqirus are already investing in their own mRNA programs or seeking ways to further enhance their existing platforms. Meanwhile, Moderna is already looking toward the future, with several combination vaccines in its pipeline—including a "super-shot" that targets both influenza and COVID-19, and another that adds respiratory syncytial virus (RSV) to the mix.
As the U.S. prepares for the rollout of mFlusiva, the international community is watching closely. The vaccine has already been accepted for regulatory review in the European Union, Canada, and Australia, with additional submissions planned for other global markets later this year. For Moderna, the approval is a validation of the company’s post-pandemic strategy. For the public, it represents the arrival of a long-promised technological evolution in the annual ritual of the flu shot, offering the hope of better protection through faster, more precise science.
